SCHEDULE 13G/A: BlackRock Discloses 0.6% Passive Stake in Elevation Oncology

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.6% of Elevation Oncology, Inc.'s common stock as of June 30, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Elevation Oncology, Inc.
• As of June 30, 2025, BlackRock, Inc. beneficially owned 369,048 shares of Elevation Oncology, Inc. Common Stock.
• This represents 0.6% of the total outstanding common stock of Elevation Oncology, Inc.
• BlackRock, Inc. holds sole voting power over 365,825 shares and sole dispositive power over 369,048 shares.
• No shared voting or dispositive power was reported.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Various persons have the right to receive dividends or proceeds from the sale of these securities, but no single person's interest exceeds five percent of the total outstanding common shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing a passive ownership stake, providing no positive or negative operational or financial news for the issuer.

Positives

• A significant institutional investor, BlackRock, Inc., holds a stake in Elevation Oncology, Inc., indicating institutional interest.

Future Outlook

NA

Industry Context

This Schedule 13G filing is a standard regulatory disclosure by a major asset management firm, BlackRock, Inc., detailing its passive investment in Elevation Oncology, Inc. Such filings are routine for large institutional investors managing diverse portfolios and do not typically reflect specific strategic industry moves beyond portfolio allocation.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which is generally neutral.
• Company Management: Awareness of a large, passive institutional investor on their shareholder register.

Key Dates

Keywords

BlackRock, Elevation Oncology, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment